MediciNova asthma drug fails trial; shares crash – Reuters

MediciNova asthma drug fails trial; shares crash
Reuters
(Reuters) – Biopharmaceutical company MediciNova Inc said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade. MediciNova, which is testing MN-221 as a
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma MarketWatch (press release)
MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary StreetInsider.com (subscription)

all 11 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.